ARGX 111

Drug Profile

ARGX 111

Alternative Names: Anti-cMet SIMPLE Antibody; ARGX-111

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 07 Jul 2017 Efficacy and adverse events data from a phase Ib trial in Cancer released by argenx
  • 01 Mar 2017 argenx completes a phase I trial in Cancer (Late-stage disease, Second-line therapy or greater) in USA(NCT02055066)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top